Novo Nordisk Invests $73 Million in Manufacturing Facility

PRINCETON, N.C. — Global pharmaceutical manufacturer Novo Nordisk is investing $73 million to expand their manufacturing facility in Clayton, N.C. The expansion will accommodate increased capacity for the company’s insulin-delivery devices.

 

Novo Nordisk has more than 420 employees in the Clayton facility who are responsible for the formulation, packaging and distribution of six different diabetes treatment products. The expected expansion will include the addition of two final assembly lines, two packing lines and building refurbishment. The expansion will create 205 new jobs, including 85 in the Novo Nordisk Clayton facility, which currently produces a variety of diabetic products, according to reports.

 

The Clayton location was chosen for expansion after an evaluation of both domestic and international facilities. Cost and production factors, including the levels of incentive support from local and state resources, were taken into account.

 

Since the launch of the company 25 years ago, Novo Nordisk has been working with physicians and patients to demonstrate the many benefits of modem delivery devices over vials and syringes.

 

Based in Denmark and with research and manufacturing facilities worldwide, Novo Nordisk is the creator of the first insulin pen and is a world leader in producing and delivering insulin delivery services.  In addition to the Clayton expansion, the company announced recently that it is doubling the size of its Research and Development facility in Beijing, China.

 

 

 

?